Key result
The Ross procedure resulted in 0% 30-day mortality, identical to propensity-matched surgical aortic valve replacement, while achieving lower mean aortic valve gradients (4 vs 9 mm Hg; P<0.01).
Why the study?
Widespread adoption of the Ross procedure has been limited by concerns over technical complexity, operative risk, and the learning curve during program development.
Does the Ross procedure have comparable 30-day mortality and improved hemodynamics compared to propensity-matched surgical aortic valve replacement during the early learning curve of a new program?
Cohort (n=100)
Does the Ross procedure have comparable 30-day mortality and improved hemodynamics compared to propensity-matched surgical aortic valve replacement during the early learning curve of a new program?
Absolute Event Rate: 0% vs 0%
Establishing a modern Ross procedure program is feasible and safe, achieving zero 30-day mortality and superior early hemodynamics compared to standard surgical aortic valve replacement despite longer operative times.
Early Ross experience appears feasible in expert hands; leaves open need for multicenter validation before wider adoption.
Background The Ross procedure (RP) is technically complex but offers superior hemodynamics and improved long-term survival compared to prosthetic aortic valve replacement, particularly in young adults. Despite these advantages, widespread adoption has been limited by concerns regarding technical complexity, operative risk, and the learning curve associated with Ross program development. This study evaluates the early experience of the first 50 RPs performed by a lead surgeon compared to propensity-matched surgical aortic valve replacement (SAVR). Methods The RP has historically been criticized for its higher operative complexity and perceived risk during the learning curve. To address this, we compared the first 50 RPs performed by a lead surgeon within a structured Ross program to 50 propensity-matched isolated SAVR patients. The primary outcome was 30-day mortality, while secondary outcomes included perioperative events, operative times, and valve hemodynamics. Results The Ross cohort was younger (42 vs 53 years, P < .01) and had lower rates of hypertension (40.0% vs 62.1%, P = .005). Twenty six cases (52%) were performed with structured two-attending mentorship. After propensity matching, no 30-day mortality was observed in either group. Ross procedures had longer cross-clamp times (183 [161-211] vs 83 [66-103] min, P < .01) but achieved lower mean aortic valve gradients (4 [3-4] vs 9 [7-12] mm Hg, P < .01) with similar lengths of stay (6 [5-7] days vs 6 [5-7] days, P = .81). Although several important perioperative technical events occurred during the Ross experience, including unplanned coronary bypass grafting and reoperation for autograft dysfunction, these events were recognized promptly and managed successfully without excess mortality or major morbidity. Conclusions Our early experience suggests that establishment of a modern Ross program is feasible with excellent early outcomes when supported by careful patient selection, structured mentorship, operative standardization, multimodality imaging, and robust institutional infrastructure. Importantly, transparent reporting of technical complications, lessons learned, and evolving perioperative strategies during the learning curve may help guide safe dissemination of the Ross procedure to additional centers.
No takes yet. Share an insight, caveat, or question.
Nam et al. (2026) conducted a cohort in Aortic valve disease (n=100). Ross procedure vs. Surgical aortic valve replacement (SAVR) was evaluated on 30-day mortality. The Ross procedure resulted in 0% 30-day mortality, identical to propensity-matched surgical aortic valve replacement, while achieving lower mean aortic valve gradients (4 vs 9 mm Hg; P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: